MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.21
−0.21%Aug 11, 2026, 23:05 UTC
Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.
Aug 11, 2026, 20:05 UTC
Mineralys Therapeutics appointed Dr. Terry Ferguson as Chief Medical Officer to lead medical and late-stage clinical activities.
Source:Jun 3, 2026, 10:05 UTC
Mineralys Therapeutics priced an underwritten offering of 5,660,378 shares of common stock at $26.50 per share, expecting gross proceeds of approximately $150 million.
Source:Jun 3, 2026, 10:00 UTC
Mineralys Therapeutics repurchased royalty obligations in the Tanabe license agreement for $200 million upfront and up to $100 million in milestones, with concurrent financing.
Jun 3, 2026, 00:00 UTC
Mineralys Therapeutics, Inc. entered into a $500 million senior secured term loan facility agreement on June 2, 2026.
May 30, 2026, 15:20 UTC
Mineralys Therapeutics presented new data at a European medical conference showing its experimental drug significantly reduced blood pressure in chronic kidney disease patients.
Source: